ScreenerHero

IRD Opus Genetics, Inc.

NAS · US · Healthcare · Biotechnology · opusgtx.com
4.410USD+0.68%Mkt Cap: 366.89M $P/E: —

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additio…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD
HeadlineSourceTime
Older
Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?

Opus Genetics, Inc. (NASDAQ:IRD) reported on September 9 that all five low-dose BIRD-1 participants showed clinically meaningful improvement on at least one visual-function measure after treatment with investigational gene therapy OPGx-BEST1. The open-label Phase 1/2 cohort included three participants with Best vitelliform macular dystrophy followed for three months and two with autosomal recessive bestrophinopathy followed […]

Insider Monkey
Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State S

MT Newswires
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial

Researchers observed structural improvements in the retina in four of five patients being evaluated in a Phase 1/2 study

Stocktwits
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027

Opus Genetics (NASDAQ:IRD) reported positive low-dose Cohort 1 data from its Phase 1/2 BIRD-1 trial of OPGx-BEST1, alongside FDA alignment on potential pivotal endpoints and a development path that could lead to Phase 3 participant dosing in 2027. Key Investor TakeawaysAll five low-dose participants showed clinically meaningful improvement in at least one measure of visual function, while four of five showed structural retinal improvements.

InvestorsHub
Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data

Opus Genetics Inc (NASDAQ:IRD) shares rose 5. 9% in pre-market trading ahead of the scheduled release of three-month topline data from Cohort 1 of its OPGx-BEST1 Phase 1/2 clinical trial.

InvestorsHub
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +6.67% and -75.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks